AIT Effectiveness on AR progression
With 27.8%, significantly more patients treated with MCT®-associated allergoids did not receive prescriptions for symptomatic AR medication in the follow up period vs. control group (covariate adjusted Odds Ratio (OR): 0.27; p < 0.001). Significant differences were also shown for allergoid 2 (19.0%, OR: 0.41; p < 0.001) and allergoid 3 (20.4%, OR: 0.33; p < 0.001) and therefore for the entire AIT treatment group (20.3%, OR: 0.37; p < 0.001, see Figure 2).
In addition, the prescriptions of symptomatic AR medication in the MCT®-associated allergoid treatment group were significantly reduced by 24.2% in the follow-up vs. baseline and control group (p < 0.001). These effects could also be demonstrated for the allergoid 2, allergoid 3 and entire AIT treatment group (21.2%, 16.9%, 20.0%, p < 0.001, see Table 2).
All endpoints were significant for children/adolescents and adults in the individual analyses.